Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Source: washingtontimes.com
Please follow and like us:
Cheaper competition for Humira is hitting the market, but savings will depend on your insurance